This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/29/2026
The cohort A initial subgroup analysis evaluated 20 patients who received CARVYKTI that was manufactured with the clinical trial process.1-4

Abbreviations: BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; Cy, cyclophosphamide; ECOG PS, Eastern Cooperative Oncology Group performance status; Flu, fludarabine; ICANS, immune effector cell-associated neurotoxicity syndrome; IMWG, International Myeloma Working Group; MM, multiple myeloma; MRD, minimal residual disease; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NGF, next-generation flow; NGS, next-generation sequencing; ORR, overall response rate; PD, pharmacodynamics; PI, proteasome inhibitor; PK, pharmacokinetics.
a
| Alive and Progression-Free for ≥5 Years (n=10) | PD or Death due to PD (n=7) | |
|---|---|---|
| Median age, years (range) | 60.5 (47-68) | 57.0 (38-61) |
| Male, n (%) | 6 (60.0) | 5 (71.4) |
| High-risk cytogenetics, n/N (%) | ||
| Any of the 5 abnormal markersa | 5/7 (71.4) | 7/7 (100.0) |
| ≥2 of the 5 abnormal markersa | 4/7 (57.1) | 3/7 (42.9) |
| Excluding gain/amp(1q) | 5/7 (71.4) | 3/7 (42.9) |
| Standard risk cytogenetics, n/N (%) | 2/7 (28.6) | 0 |
| Median bone marrow plasma cellsb | 20.0 (1.0-95.0) | 40.0 (4.7-95.0) |
| % bone marrow plasma cellsb, n (%) | ||
| ≤30% | 9 (90.0) | 3 (42.9) |
| >30% to <60% | 0 | 2 (28.6) |
| ≥60% | 1 (10.0) | 2 (28.6) |
| Median soluble BCMAc | 14.1 (4.3-982.3) | 68.2 (7.4-132.6) |
| Any decrease in tumor burden from screening to CARVYKTI infusiond | 6 (60.0) | 3 (42.9) |
| Presence of soft tissue plasmacytomasᵉ, n (%) | 2 (20.0) | 1 (14.3) |
| Median previous LOT, range | 2 (1-3) | 3 (1-3) |
| Prior ASCT, n (%) | 9 (90.0) | 5 (71.4) |
| Triple-class exposureᶠ, n (%) | 5 (50.0) | 6 (85.7) |
| Triple-class refractoryᶠ, n (%) | 4 (40.0) | 3 (42.9) |
| Daratumumab exposed, n (%) | 5 (50.0) | 6 (85.7) |
| Daratumumab refractory, n (%) | 5 (50.0) | 5 (71.4) |
| Median time from start of last LOT to progression on that line, months (range) | 12.8 (1.5-43.2) | 5.7 (1.0-41.7) |
| Abbreviations: ASCT, autologous stem cell transplantation; BCMA, B-cell maturation antigen; CD, cluster of differentiation; FLC, free light chain; LOT, line of therapy; PD, progressive disease; PI, proteasome inhibitor.aThe 5 abnormal markers are: del(17p), t(4;14), t(14;16), t(14;20), gain/amp(1q). bMaximum value from bone marrow biopsy and bone marrow aspirate was selected if both results were available. cLast non-missing record on or before CARVYKTI infusion. dTumor burden between screening and CARVYKTI infusion was measured based on the patient's baseline measurable disease: serum M-protein, urine M-protein, or difference between involved and uninvolved FLC. e f | ||
| Events, n (%) | Updated Safety Resultsa (N=20) |
|---|---|
| Second primary malignancy (not related to CARVYKTI)b | 5 (25.0) |
| Acute myeloid leukemia | 1 (5.0) |
| Breast cancer | 1 (5.0) |
| Prostate cancer | 1 (5.0) |
| Basal cell carcinoma | 1 (5.0) |
| Malignant melanoma stage 0 (melanoma in situ) | 1 (5.0) |
| Squamous cell carcinoma | 1 (5.0) |
| CAR T-cell-related neurotoxicity | |
| Cranial nerve palsies | 0 |
| Parkinsonism | 0 |
| Overall mortality | 2 (10.0) |
| Death due to AE | 1 (5.0)c |
| Abbreviations: AE, adverse event; CAR, chimeric antigen receptor. aData newly reported since the 30-month follow-up. bOne patient had 2 second primary malignancies: basal cell carcinoma and malignant melanoma stage 0. cThe patient who died due to breast cancer was alive and progression-free at 5 years. | |
| Total (N=20) | |
|---|---|
| Median age (range), years | 60 (38-75) |
| Male, n (%) | 13 (65.0) |
| Race, n (%) | |
| White | 18 (90.0) |
| Black/African American | 2 (10.0) |
| Asian | 0 |
| Not reported | 0 |
| Extramedullary plasmacytomas ≥1, n (%) | 3 (15.0) |
| Bone marrow plasma cellsa, ≥60%, n (%) | 3 (15.0) |
| High-risk cytogenetic profile, n (%) | 7 (35.0)b |
| del17p | 3 (15.0) |
| t(14;16) | 5 (25.0) |
| t(4;14) | 0 |
| 1q | 0 |
| Median years since diagnosis (range) | 3.5 (0.7-8.0) |
| Median prior lines of therapy, n (range) | 2 (1-3) |
| Prior stem-cell transplantation, n (%) | |
| Autologous | 17 (85.0) |
| Allogenic | 0 |
| Triple-class exposedc, n (%) | 13 (65.0) |
| Penta-drug exposedd, n (%) | 4 (20.0) |
| Refractory status, n (%) | |
| Carfilzomib | 2 (10) |
| Pomalidomide | 7 (35) |
| Bortezomib | 8 (40) |
| Daratumumab | 12 (60) |
| Triple-class refractoryc | 8 (40.0) |
| Penta-drug refractoryd | 1 (5.0) |
| Refractory to last line of therapy | 19 (95.0) |
| aMaximum value from bone marrow biopsy and bone marrow aspirate is selected if both results are available. bOne patient had both del17p and t(14:16); 6 patients had unknown cytogenetics. cAt least 1 proteasome inhibitor, at least 1 immunomodulatory drug, and 1 anti-CD38 antibody. d≥2 proteasome inhibitors, ≥2 immunomodulatory drugs, and 1 anti-CD38 antibody. | |
| Parameter | N=20 | |||
|---|---|---|---|---|
| Median Follow-up | ||||
| 5.8 Months | 14.3 Months | 17.1 Months | 29.9 Months | |
| ORR, % (95% CI) | 95 (75-100) | 95 (75.1-99.9) | 95 (75.1-99.9) | 95 - |
| sCR, % (95% CI) | 45 | 75 | 85 (62.1-96.8) | 85 |
| CR, % | 30 | 10 | 5 | 5 |
| VGPR, % | 10 | 5 | 5 | 5 |
| PR, % | 10 | 5 | - | - |
| Evaluable patients for overall MRD negativitya, n | 4 | 13 | 16 | 17 |
| Overall MRD-negative at 10-5 sensitivity level, % (95% CI) | 100 | 92 (64.0-99.8) | 100 (79.4-100) | 100 |
| Median time to first response, months (range) | 1.0 (0.7-3.3) | 1.0 (0.7-3.3) | 1.0 (0.7-3.3) | 0.99 (0.7-3.3) |
| Median time to best response, months (range) | 1.9 (0.9-5.1) | 2.6 (0.9-7.9) | 2.6 (0.9-13.6) | 3.25 (0.9-13.6) |
| Median DOR, months (95% CI) | NR | NR | NRb | - |
| Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; MRD, minimal residual disease; NE, not estimable; NGF, next-generation flow; NGS, next-generation sequencing; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; sCR, stringent complete response; VGPR, very good partial response. aPatients who were MRD evaluable had a clone identified and had at least one post-baseline MRD sample that included sufficient cells for evaluation at the 10-5 testing threshold (for NGS) or patients who had at least one post-baseline sample with the result of either positive or negative (for NGF). bEstimated 90% of responders remained in response for 12 months. | ||||

Abbreviations: CI, confidence interval; no., number; PFS, progression-free survival; OS, overall survival.
Cytokine Release Syndrome
Neurotoxicity
| N=20 | ||
|---|---|---|
| Any Grade | Grade 3/4 | |
| Metabolism and nutrition disorders | ||
| Hypokalemia | 9 (45) | 0 |
| Hypocalcemia | 8 (40) | 3 (15) |
| Hypophosphatemia | 7 (35) | 4 (20) |
| Hypomagnesemia | 6 (30) | 0 |
| Decreased appetite | 5 (25) | 3 (15) |
| Gastrointestinal | ||
| Diarrhea | 8 (40) | 3 (15) |
| Nausea | 6 (30) | 0 |
| Constipation | 4 (20) | 0 |
| Vomiting | 4 (20) | 0 |
| Other | ||
| Fatigue | 8 (40) | 0 |
| Back pain | 6 (30) | 2 (10) |
| Gamma-glutamyl transferase increase | 4 (20) | 1 (5) |
| Weight decreased | 4 (20) | 1 (5) |
| Pyrexia | 4 (20) | 0 |
| Arthralgia | 4 (20) | 0 |
| Renal Impairment | 4 (20) | 0 |
| Abbreviations: AE, adverse event. aIncidence and severity of adverse events were assessed per Common Terminology criteria for AEs version 5.0. bMedian follow-up of 14.3 months. | ||
| Eventa , n (%) | N=20 | |
|---|---|---|
| Any Grade | Grade 3/4 | |
| Neutropenia | 19 (95.0) | 19 (95.0) |
| Lymphopenia | 16 (80.0) | 16 (80.0) |
| Thrombocytopenia | 16 (80.0) | 8 (40.0) |
| Anemia | 15 (75.0) | 9 (45.0) |
| Leukopenia | 12 (60.0) | 12 (60.0) |
| aMedian follow-up of 29.9 months. | ||
| Total (N=20) | |
|---|---|
| Patients with a CRS event (any grade)a, n (%) | 19 (95) |
| Patients with CRS (Grade 3/4)a, n (%) | 2 (10) |
| Median time to onset of CRS, days (range) | 7 (5-9) |
| Median duration of CRS, days (range) | 3 (2-12) |
| Supportive Measuresb, n (%) | |
| Tocilizumab | 14 (70) |
| IV fluids | 8 (40) |
| Corticosteroids | 6 (30) |
| Oxygen | 4 (20) |
| Anakinra | 1 (5) |
| Vasopressor | 1 (5) |
| Abbreviations: CRS, cytokine release syndrome; IV, intravenous. aCRS was graded according to the American Society for Transplantation and Cellular Therapy criteria. bIncludes supportive measures to treat CRS events and symptoms. | |
| Total (N=20) | ||
|---|---|---|
| Any Grade | Grade 3/4 | |
| Neurotoxicity, n (%) | 6 (30.0) | 1 (5.0) |
| ICANSa, n (%) | 3 (15.0) | 0 |
| Other neurotoxicitiesb, n (%) | 3(15.0)c | 1 (5.0) |
| MNT | 0 | 0 |
| Abbreviations: AE, adverse event; CRS, cytokine release syndrome; ICANS, Immune effector cell-associated neurotoxicity syndrome; MNT, movement and neurocognitive treatment-emergent adverse event. aICANS was graded according to the American Society for Transplantation and Cellular Therapy criteria. bEvents not reported as ICANS (ie, onset after a period of recovery from CRS and/or ICANS). c1 case each of peripheral sensorimotor neuropathy (recovering/resolving), anosmia (resolved), and facial paralysis (resolved). | ||
The CARTITUDE-2 cohort A study evaluating the efficacy and safety of CARVYKTI in patients who had progressive MM after 1-3 prior LOT and were refractory to lenalidomide was expanded to assess CARVYKTI manufactured with a commercial process (expansion subgroup).6
The cohort A expansion subgroup analysis evaluated 23 patients who received CARVYKTI that was manufactured with a commercial process.6
| Characteristic | N=23 |
|---|---|
| Age, median (range), years | 63 (37-74) |
| Male, n (%) | 12 (52.2) |
| Race, n (%) | |
| White | 15 (65.2) |
| Black | 2 (8.7) |
| Asian | 1 (4.3) |
| American Indian or Alaska native | 1 (4.3) |
| Not reported | 4 (17.4) |
| ECOG score at screening, n (%) | |
| 0 | 15 (65.2) |
| 1 | 8 (34.8) |
| ISS Stage at baseline, n (%) | |
| I | 17 (73.9) |
| II | 2 (8.7) |
| III | 4 (17.4) |
| Bone marrow plasma cells, ≥60%, n (%)a | 3 (13.6) |
| Soft tissue plasmacytomas, n (%) | 4 (17.4) |
| High-risk cytogenetic at baselineb, n (%) | 4 (17.4) |
| del17p | 2 (8.7) |
| t(14;16) | 3 (13.0) |
| Years since diagnosis, median (range) | 3.9 (0.7-11.1) |
| Median prior LOT, median (range) | 3 (1-3) |
| Prior lot, n (%) | |
| 1 | 7 (30.4) |
| 2 | 4 (17.4) |
| 3 | 12 (52.2) |
| Previous ASCT | 19 (82.6) |
| Exposure status, n (%) | |
| Daratumumab | 14 (60.9) |
| Triple-classc | 14 (60.9) |
| Penta-drugd | 6 (26.1) |
| Refractory status, n (%) | |
| Triple-classc | 10 (43.5) |
| Penta-drugd | 3 (13.0) |
| Last LOT | 22 (95.7) |
| Abbreviations: ASCT, autologous stem cell transplant; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; LOT, line of therapy; PI, proteasome inhibitor. aMaximum value from bone marrow biopsy and bone marrow aspirate is selected if both the results are available (n=22). b1 patient had more than 1 high-risk cytogenetic feature and no patients had t(4;14). cIncludes 1 PI, 1 immunomodulatory drug, and 1 anti-CD38 monoclonal antibody. dIncludes ≥2 PIs, ≥2 immunomodulatory drugs, and 1 anti-CD38 monoclonal antibody. | |
| Parameter | N=22 |
|---|---|
| 90.9 | |
| sCR | 63.6 |
| CR | 4.5 |
| VGPR | 4.5 |
| PR | 18.2 |
| ≥CR | 68.2 |
| MRD-negative CR/sCRa | 59.1 |
| Evaluable patients for overall MRD negativity, n (%; 95% CI) | 16 (72.7; 49.8-89.3) |
| Overall MRD-negative at 10-5 sensitivity level, % (95% CI) | 100 (79.4-100.0) |
| Median time to MRD negativity, years (range) | 1.9 (1.0-12.3) |
| Time to first response, median (range), monthsa | 1.0 (0.9-9.8) |
| Time to best response, median (range), monthsa | 6.2 (0.9-18.9) |
| DORa | |
| Median DOR (95% CI)a | NR (NE-NE) |
| 12-month DOR rate, % (95% CI)a | 78.8 (52.7-91.5) |
| Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; MRD, minimal residual disease; NE, not estimable; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression free survival; PR, partial response; sCR, stringent complete response; VGPR, very good partial response. aN=20, determined among patients with a ≥PR. | |
Cytokine Release Syndrome
Neurotoxicity
| Select TEAEs by maximum severity, n (%) | N=23 | |
|---|---|---|
| Any Grade | Grade 3 or 4 | |
| Any TEAEa | 23 (100.0) | 22 (95.7) |
| Hematologic | 23 (100.0) | 23 (100.0) |
| Neutropenia | 22 (95.7) | 22 (95.7) |
| Leukopenia | 15 (65.2) | 15 (65.2) |
| Lymphopenia | 15 (65.2) | 14 (60.9) |
| Anemia | 13 (56.5) | 9 (39.1) |
| Thrombocytopenia | 13 (56.5) | 9 (39.1) |
| Infections | 8 (34.8) | 1 (4.3) |
| AEs of special interest | ||
| CRS | 23 (100.0) | 0 |
| Neurotoxicity | 4 (17.4) | 1 (4.3) |
| ICANS | 4 (17.4) | 1 (4.3) |
| Other neurotoxicitiesb | 0 | 0 |
| MNTs/parkinsonism | 0 | 0 |
| Abbreviations: AE, adverse event; CAR-T, chimeric antigen receptor T-cell; CRS, cytokine release syndrome; ICANS, immune effector cell associated neurotoxicity syndrome; MNT, movement and neurocognitive treatment-emergent adverse event; TEAE, treatment-emergent adverse event. a1 patient had a maximum treatment emergent adverse event of grade 5 sepsis. bOther neurotoxicites were defined as neurological adverse events determined by the investigator to be related to CAR-T cell therapy and occurring after recovery of CRS and/or ICANS. | ||
A literature search of MEDLINE®
1. Agha M, Cohen A, Madduri D, et al. CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma after 1-3 prior lines of therapy. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021; Virtual.
2. Cohen Y, Cohen A, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Poster presented at: 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11-14, 2021; Atlanta, GA/Virtual.
3. Einsele H, Cohen A, Delforge M, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2, Cohort A. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2022; Chicago, IL/Virtual.
4. Hillengass J, Cohen AD, Agha M, et al. The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1–3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B). Oral Presentation presented at: 65th American Society of Hematology (ASH) Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA.
5. Cohen AD, Mateos MV, Cohen YC, et al. Long-term (≥5-year) remission and survival with ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (RRMM) with 1-3 prior lines of therapy: CARTITUDE-2 Cohort A. Poster presented at: the 23rd International Myeloma Society (IMS) Annual Meeting; September 23-26, 2026; Glasgow, Scotland.
6. Cohen A, Voorhees P, Martin T, et al. Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup. Poster presented at: American Society of Clinical Oncology; May 31-June 4, 2024; Chicago, IL.
7. Janssen Research & Development, LLC. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with multiple myeloma (CARTITUDE-2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 July 30] Available from: https://clinicaltrials.gov/ct2/show/NCT04133636 NLM Identifier: NCT04133636.
8. Einsele H, Parekh S, D M. Incidence, mitigation, and management of neurologic adverse events in patients With multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE-2. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021; Virtual.
9. van de Donk NWCJ, Sidana S, Schecter JM, et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel. Poster presented at: 65th American Society of Hematology (ASH) Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA.
10. Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32.
Would you like to clear and leave your conversation? Message history will be lost.